Literature DB >> 4031970

Central nervous system pharmacokinetics of high-dose cytosine arabinoside.

J A Lopez, E Nassif, P Vannicola, J G Krikorian, R P Agarwal.   

Abstract

The cerebrospinal fluid (CSF) pharmacokinetics of cytosine arabinoside (Ara-C) was determined in 8 patients with metastatic cancer in the central nervous system. High dose (3 gm/M2) one-hour intravenous infusions of Ara-C were given with serial CSF sampling obtained from indwelling Ommaya reservoirs. CSF was analyzed by high pressure liquid chromatography. Mean Ara-C elimination half life of 140 minutes in CSF was eight times longer than that in plasma. The peak mean CSF concentration of Ara-C (2.1 micrograms /ml) was about 7% of the plasma concentration (30 micrograms/ml). A total of 28 treatment courses were administered with minimal hematopoietic, gastrointestinal and neurological toxicities. A schedule of administration of 2 high-dose treatments 12 hours apart repeated every two weeks should maintain cytotoxic CSF concentrations which could prove useful in the management of CNS leukemia and lymphoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031970     DOI: 10.1007/bf02228887

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  14 in total

1.  Chemotherapy of brain tumors.

Authors:  N A Vick; J D Khandekar; D D Bigner
Journal:  Arch Neurol       Date:  1977-09

2.  Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.

Authors:  D H Ho; E Frei
Journal:  Clin Pharmacol Ther       Date:  1971 Nov-Dec       Impact factor: 6.875

3.  Effects of high-dose cytarabine.

Authors:  K R Hande; R S Stein; D A McDonough; F A Greco; S N Wolff
Journal:  Clin Pharmacol Ther       Date:  1982-05       Impact factor: 6.875

4.  Simple and rapid high-performance liquid chromatographic method for analysis of nucleosides in biological fluids.

Authors:  R P Agarwal; P P Major; D W Kufe
Journal:  J Chromatogr       Date:  1982-09-10

5.  High dose cytosine arabinoside (HDARAC) in refractory acute leukemia.

Authors:  S A Rudnick; E C Cadman; R L Capizzi; R T Skeel; J R Bertino; S McIntosh
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

6.  Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.

Authors:  J A Lopez; G P Beardsley; J G Krikorian; R W Mortara; R P Agarwal
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

7.  Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside.

Authors:  H J Weinstein; T W Griffin; J Feeney; H J Cohen; R D Propper; S E Sallan
Journal:  Blood       Date:  1982-06       Impact factor: 22.113

8.  Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.

Authors:  M L Slevin; E M Piall; G W Aherne; V J Harvey; A Johnston; T A Lister
Journal:  J Clin Oncol       Date:  1983-09       Impact factor: 44.544

9.  A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.

Authors:  A P Early; H D Preisler; H Slocum; Y M Rustum
Journal:  Cancer Res       Date:  1982-04       Impact factor: 12.701

10.  Drugs five years later: cytarabine.

Authors:  W B Kremer
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

View more
  13 in total

Review 1.  Intrathecal chemotherapy with antineoplastic agents in children.

Authors:  A Ruggiero; V Conter; M Milani; E Biagi; I Lazzareschi; P Sparano; R Riccardi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis.

Authors:  Stacey L Berg; Marc C Chamberlain
Journal:  Curr Oncol Rep       Date:  2003-01       Impact factor: 5.075

3.  Treatment and prophylaxis of hematologic malignancy in the central nervous system.

Authors:  Seema Nagpal; Lawrence Recht
Journal:  Curr Treat Options Neurol       Date:  2011-08       Impact factor: 3.598

4.  Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.

Authors:  Tieran Han; Marilyn Fernandez; Ting-Chao Chou; Ram P Agarwal
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

5.  Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome.

Authors:  Jai Grewal; Marlon Saria; Harpreet K Grewal; Santosh Kesari
Journal:  Clin Investig (Lond)       Date:  2011-10

6.  AIDS-related central nervous system lymphomas.

Authors:  M C Chamberlain; P A Kormanik
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

Review 7.  Current pharmacological treatment approaches to central nervous system leukaemia.

Authors:  S M Blaney; F M Balis; D G Poplack
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

8.  Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis. A morphologic and adriamycin-penetration study.

Authors:  T Siegal; U Sandbank; A Gabizon; T Siegal; R Mizrachi; E Ben-David; R Catane
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

Review 9.  Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?

Authors:  T Siegal
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

10.  Treatment of leptomeningeal spread of NSCLC: a continuing challenge.

Authors:  Seema Nagpal; Jonathan Riess; Heather Wakelee
Journal:  Curr Treat Options Oncol       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.